- Event will feature
Aravindhan Veerapandiyan, M.D., principal investigator of the
AFFINITY DUCHENNE® trial and Michael Kelly, PhD, Chief Scientific Officer of
CureDuchenne
ROCKVILLE, Md., Nov. 14,
2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced that it will host a webcast to discuss the AFFINITY
DUCHENNE® pivotal program and new clinical data,
including the first functional data from the ongoing Phase I/II
study of RGX-202, the company's next-generation gene therapy for
the treatment of Duchenne muscular dystrophy. The webcast will
feature AFFINITY DUCHENNE principal investigator Aravindhan
Veerapandiyan, M.D., Arkansas Children's Hospital, and Michael Kelly, PhD, Chief Scientific Officer of
CureDuchenne.
Webcast details
Title: AFFINITY DUCHENNE
Trial of RGX-202: Pivotal Program and Interim Clinical Data
Date/Time: Monday, November 18,
2024, at 8:00 a.m. EST
Access: The live webcast can be accessed here and
in the Investors section of REGENXBIO's website at
www.regenxbio.com. An archived replay of the webcast will be
available for approximately 30 days following the presentation.
These updates will also be presented at the American Society of
Gene and Cell Therapy and Muscular Dystrophy Association 2024
Breakthroughs in Muscular Dystrophy conference November 19, 2024, in Chicago.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. Since its founding in 2009, REGENXBIO has
pioneered the development of AAV Therapeutics, an innovative class
of gene therapy medicines. REGENXBIO is advancing a
pipeline of AAV Therapeutics for rare and retinal diseases,
including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for
the treatment of wet AMD and diabetic retinopathy, being developed
in collaboration with AbbVie, and RGX-121 for the treatment of MPS
II. Thousands of patients have been treated
with REGENXBIO's AAV Therapeutic platform, including
Novartis' Zolgensma® for children with spinal
muscular atrophy. Designed to be one-time treatments, AAV
Therapeutics have the potential to change the way healthcare is
delivered for millions of people. For more information, please
visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-webcast-discussing-pivotal-program-and-first-functional-data-from-the-affinity-duchenne-trial-of-rgx-202-302305167.html
SOURCE REGENXBIO Inc.
